WallStreetZenWallStreetZen

NASDAQ: CARM
Carisma Therapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for CARM

Based on 4 analysts offering 12 month price targets for Carisma Therapeutics Inc

Min Forecast
$0.70+270.37%
Avg Forecast
$1.93+918.52%
Max Forecast
$5.00+2,545.5%

Should I buy or sell CARM stock?

Based on 4 analysts offering ratings for Carisma Therapeutics Inc.

Buy
Strong Buy
1 analysts 25%
Buy
1 analysts 25%
Hold
2 analysts 50%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their CARM stock forecasts and price targets.

CARM stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-04-01
lockedlocked$00.00+00.00%2024-12-12
lockedlocked$00.00+00.00%2024-12-11
lockedlocked$00.00+00.00%2024-11-25

1 of 1

Forecast return on equity

Is CARM forecast to generate an efficient return?

Insufficient data to display

Forecast return on assets

Is CARM forecast to generate an efficient return on assets?

Company
-226.38%
Industry
36.07%
CARM is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

CARM earnings per share forecast

What is CARM's earnings per share in the next 2 years based on estimates from 1 analyst?

Avg 1 year Forecast
-$1.00
Avg 2 year Forecast
-$0.74

CARM revenue forecast

What is CARM's revenue in the next 3 years based on estimates from 1 analyst?

Avg 1 year Forecast
$21.7M+10.53%
Avg 2 year Forecast
$10.0M-49.16%
Avg 3 year Forecast
$35.2M+79.4%
CARM's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

CARM revenue growth forecast

How is CARM forecast to perform vs Biotechnology companies and vs the US market?

Company
75.28%
Industry
65.48%
Market
10.37%
CARM's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
CARM's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

CARM vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
CARM$0.19$1.93+918.52%Buy
PMCB$1.13N/AN/A
APRE$1.47$20.00+1,260.54%Buy
ACXP$0.37$12.00+3,152.03%Buy
TSBX$0.33N/AN/A
View Top Biotech Stocks

Carisma Therapeutics Stock Forecast FAQ

Is Carisma Therapeutics Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 4 Wall Street analysts covering (NASDAQ: CARM) stock is to Buy CARM stock.

Out of 4 analysts, 1 (25%) are recommending CARM as a Strong Buy, 1 (25%) are recommending CARM as a Buy, 2 (50%) are recommending CARM as a Hold, 0 (0%) are recommending CARM as a Sell, and 0 (0%) are recommending CARM as a Strong Sell.

If you're new to stock investing, here's how to buy Carisma Therapeutics stock.

What is CARM's earnings growth forecast for 2025-2026?

(NASDAQ: CARM) Carisma Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 13.28%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 18.17%.

Carisma Therapeutics's earnings in 2025 is -$60,477,000.On average, 1 Wall Street analyst forecast CARM's earnings for 2025 to be -$41,788,096, with the lowest CARM earnings forecast at -$41,788,096, and the highest CARM earnings forecast at -$41,788,096.

In 2026, CARM is forecast to generate -$30,923,191 in earnings, with the lowest earnings forecast at -$30,923,191 and the highest earnings forecast at -$30,923,191.

What is CARM's revenue growth forecast for 2025-2029?

(NASDAQ: CARM) Carisma Therapeutics's forecast annual revenue growth rate of 75.28% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 65.48%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.37%.

Carisma Therapeutics's revenue in 2025 is $19,632,000.On average, 1 Wall Street analysts forecast CARM's revenue for 2025 to be $906,801,683, with the lowest CARM revenue forecast at $906,801,683, and the highest CARM revenue forecast at $906,801,683. On average, 1 Wall Street analysts forecast CARM's revenue for 2028 to be $417,045,198, with the lowest CARM revenue forecast at $417,045,198, and the highest CARM revenue forecast at $417,045,198.

In 2029, CARM is forecast to generate $1,471,776,741 in revenue, with the lowest revenue forecast at $1,471,776,741 and the highest revenue forecast at $1,471,776,741.

What is CARM's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: CARM) forecast ROA is -226.38%, which is lower than the forecast US Biotechnology industry average of 36.07%.

What is CARM's Price Target?

According to 4 Wall Street analysts that have issued a 1 year CARM price target, the average CARM price target is $1.93, with the highest CARM stock price forecast at $5.00 and the lowest CARM stock price forecast at $0.70.

On average, Wall Street analysts predict that Carisma Therapeutics's share price could reach $1.93 by Apr 1, 2026. The average Carisma Therapeutics stock price prediction forecasts a potential upside of 918.52% from the current CARM share price of $0.19.

What is CARM's Earnings Per Share (EPS) forecast for 2025-2026?

(NASDAQ: CARM) Carisma Therapeutics's current Earnings Per Share (EPS) is -$1.46. On average, analysts forecast that CARM's EPS will be -$1.00 for 2025, with the lowest EPS forecast at -$1.00, and the highest EPS forecast at -$1.00. In 2026, CARM's EPS is forecast to hit -$0.74 (min: -$0.74, max: -$0.74).

What is CARM's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: CARM) forecast ROE is N/A, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.